Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis.
نویسندگان
چکیده
منابع مشابه
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinica...
متن کاملTocilizumab, an interleukin-6 inhibitor: a steroid sparing agent in giant cell arteritis.
The Giant Cell Arteritis Actemra (GiACTA) study, the largest randomised trial for this disease to date, involved 251 patients and describes the benefits of tocilizumab, an interleukin-6 inhibitor.1 Patients were randomised to one of 4 groups, in a ratio of 2:1:1:1, to receive: subcutaneous tocilizumab 162 mg weekly (100 patients); or every 2 weeks (50 patients); or placebo (one arm of 50 patien...
متن کاملBiological agents for giant cell arteritis: treat to target.
In a case series published in the Annals of the Rheumatic Diseases, Conway et al reported a significant steroid-sparing effect of ustekinumab (monoclonal antibody to interleukin (IL)-12 and IL-23) in 14 patients with giant cell arteritis (GCA). Recently, Ferfar et al summarised current evidence showing the efficacy of tocilizumab and abatacept in patients with GCA. In the ongoing multicentre, r...
متن کاملGiant cell arteritis in Mumbai.
OBJECTIVE To study the clinical profile of patients with giant cell arteritis in Mumbai. METHODS From our database, patients with a diagnosis of giant cell arteritis (GCA) over a fifteen year period (January 1990 to December 2005) were included. Clinical manifestations, temporal artery biopsy, treatment, and follow-up data of these patients were analyzed. RESULTS Twenty one patients with GC...
متن کاملSteroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis
Although a glucocorticoid (GC)-sparing strategy is needed for patients with giant cell arteritis (GCA) suffering from refractory disease or serious treatment-related complications, evidence of efficacy in this setting of immunosuppressive drugs and biotherapies is lacking. Herein, we evaluated the GC-sparing effects and tolerability of addition of dapsone (DDS) to prednisone therapy in patients...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of rheumatology
دوره 38 9 شماره
صفحات -
تاریخ انتشار 2011